


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

CLARIFICATION ANNOUNCEMENT

References are made to the Chinese version of (i) the announcement (the “**Announcement**”) and (ii) the list of directors and their roles and functions (the “**List**”) of Kontafarma China Holdings Limited (the “**Company**”), both dated 7 June 2024.

The Company would like to clarify that the title of Mr. Wang Feifei should be “總裁” instead of “行政總裁” as stated in the Announcement. Therefore, all references made to “行政總裁” in the Chinese version of the Announcement and the List should be revised to “總裁”.

Save as disclosed herein, all other contents of both the English and Chinese versions of the Announcement and the List remain unchanged.

By order of the Board of
Kontafarma China Holdings Limited
Wang Feifei
Chairman

Hong Kong, 11 June 2024

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Feifei (Chairman and President), Ms. Qiao Linna, Ms. Guo Zixiu (Financial Controller) and Mr. Liu Jiankun; one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.